Study of a new drug for cirrhosis from fatty liver disease
Part of Digestive system clinical trials.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have at least 2 signs of metabolic syndrome (like high blood pressure, high blood sugar, excess belly fat, high triglycerides, or low good cholesterol).
- A liver biopsy has confirmed you have cirrhosis (scarring) caused by MASH (fatty liver disease).
- You do not have other causes of liver disease or a history of serious liver problems (like fluid in the belly or bleeding from the gut).
- You do not have type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.